For research use only. Not for therapeutic Use.
Anrukinzumab（Cat No.:I042175）is an investigational monoclonal antibody that targets IL-23 (interleukin-23), a pro-inflammatory cytokine involved in immune responses and the pathogenesis of several autoimmune diseases. By inhibiting IL-23, anrukinzumab aims to reduce inflammation and modulate the immune system, potentially providing therapeutic benefits in conditions like psoriasis, inflammatory bowel disease (IBD), and other chronic inflammatory disorders. It is being studied in clinical trials to assess its safety, efficacy, and ability to improve symptoms in patients with autoimmune conditions, offering a promising treatment option for managing inflammation-related diseases.
| Catalog Number | I042175 |
| CAS Number | 910649-32-0 |
| Purity | ≥95% |
